高级检索
当前位置: 首页 > 详情页

Relative Risk of Cardiovascular Mortality in Breast Cancer Patients: A Population-Based Study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Dept Breast Surg,Sch Med, Chengdu 610044, Sichuan, Peoples R China [2]Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Lab Mol Diag Canc, Chengdu 610041, Sichuan, Peoples R China [3]Sichuan Univ, West China Sch Med, Dept Breast Surg, West China Hosp, Chengdu 610041, Sichuan, Peoples R China [4]Sichuan Univ, West China Hosp, Canc Ctr, Dept Head Neck & Mammary Gland Oncol, Chengdu 610041, Sichuan, Peoples R China [5]Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610041, Sichuan, Peoples R China
出处:
ISSN:

关键词: breast cancer cardiovascular disease mortality population

摘要:
Aims: To investigate the risk of cardiovascular disease (CVD) mortality in breast cancer patients compared with the general female population. Methods: Data was retrieved from the Surveillance. Epidemiology, and End Results database. 924,439 female breast cancer patients who were at the age of follow-up >= 30 years and diagnosed during 1990-2016 as well as the aggregated general female population in the US were included. Using multivariable Poisson regression, we calculated incidence rate ratios (IRRs) of CVD mortality among female breast cancer patients compared with the female population. Results: The risk of CVD mortality was mildly increased among breast cancer patients at the age of follow-up 30-64 years (IRR 1.06, 95% confidence interval [CI] 1.03 -1.10) compared with the general population. This growth of risk reached its peak within the first month after diagnosis (IRR 3.33, 95% CI 2.84-3.91) and was mainly activated by diseases of the heart (IRR 1.11, 95% CI 1.07-1.15). The elevation was greatest in survivors at the age of follow up 30-34 years (IRR 3.50, 95% CI 1.75-7.01). Conclusions: Clinicians should provide risk mitigation strategies with early monitoring of CVD mortality for breast cancer survivors, especially those who were young or with aggressive tumor stage.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
最新[2023]版
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
JCR分区:
出版当年[2022]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Dept Breast Surg,Sch Med, Chengdu 610044, Sichuan, Peoples R China [2]Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Lab Mol Diag Canc, Chengdu 610041, Sichuan, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43372 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号